Ranibizumab or Bevacizumab for Neovascular AgeRelated Macular Degeneration

Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol Karina Berg, MD, Emina Hadzalic, MD, Inger Gjertsen, MD, Vegard Forsaa, MD, Lars Haakon Berger, MD, Bettina Kinge, MD, Ph. D, Hans Henschien, MD, Kristian Fossen, MD, Slavica Markovic, MD, Terje R. Pedersen, MD, Ph. D, Leiv Sandvik, MD, Ph. D, Ragnheiður Bragadóttir, MD, Ph. D Ophthalmology Volume 123 Issue 1 Pages 51 -59 (January 2016) DOI: 10. 1016/j. ophtha. 2015. 09. 018 Copyright © 2016 American Academy of Ophthalmology Terms and Conditions

Figure 1 Ophthalmology 2016 12351 -59 DOI: (10. 1016/j. ophtha. 2015. 09. 018) Copyright © 2016 American Academy of Ophthalmology Terms and Conditions

Figure 2 Ophthalmology 2016 12351 -59 DOI: (10. 1016/j. ophtha. 2015. 09. 018) Copyright © 2016 American Academy of Ophthalmology Terms and Conditions

Figure 3 Ophthalmology 2016 12351 -59 DOI: (10. 1016/j. ophtha. 2015. 09. 018) Copyright © 2016 American Academy of Ophthalmology Terms and Conditions

Figure 4 Ophthalmology 2016 12351 -59 DOI: (10. 1016/j. ophtha. 2015. 09. 018) Copyright © 2016 American Academy of Ophthalmology Terms and Conditions

Figure 5 Ophthalmology 2016 12351 -59 DOI: (10. 1016/j. ophtha. 2015. 09. 018) Copyright © 2016 American Academy of Ophthalmology Terms and Conditions